Insmed Company Profile (NASDAQ:INSM)

About Insmed (NASDAQ:INSM)

Insmed logoInsmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC). Its earlier-stage pipeline includes preclinical compounds that the Company is evaluating in multiple rare diseases of unmet medical need, including methicillin-resistant staph aureus and NTM. Its earlier clinical-stage pipeline includes INS1007 and INS1009. INS1007 is an oral, reversible inhibitor of dipeptidyl peptidase 1. INS1009 is an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. It has completed a Phase I study of INS1009.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:INSM
  • CUSIP: N/A
  • Web:
  • Market Cap: $1.77 billion
  • Outstanding Shares: 62,377,000
Average Prices:
  • 50 Day Moving Avg: $17.85
  • 200 Day Moving Avg: $17.15
  • 52 Week Range: $10.21 - $31.39
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -12.86
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.34 per share
  • Price / Book: 21.21
  • EBIDTA: ($180,870,000.00)
  • Return on Equity: -130.41%
  • Return on Assets: -85.48%
  • Debt-to-Equity Ratio: 0.66%
  • Current Ratio: 3.67%
  • Quick Ratio: 3.67%
  • Average Volume: 1.37 million shs.
  • Beta: 0.74
  • Short Ratio: 5.54

Frequently Asked Questions for Insmed (NASDAQ:INSM)

What is Insmed's stock symbol?

Insmed trades on the NASDAQ under the ticker symbol "INSM."

How were Insmed's earnings last quarter?

Insmed, Inc. (NASDAQ:INSM) announced its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.72) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.63) by $0.09. View Insmed's Earnings History.

Where is Insmed's stock going? Where will Insmed's stock price be in 2017?

7 brokers have issued 1-year price objectives for Insmed's stock. Their predictions range from $17.00 to $54.00. On average, they anticipate Insmed's share price to reach $36.71 in the next twelve months. View Analyst Ratings for Insmed.

Who are some of Insmed's key competitors?

Who are Insmed's key executives?

Insmed's management team includes the folowing people:

  • William H. Lewis, President, Chief Executive Officer, Director
  • Paolo Tombesi, Chief Financial Officer
  • S. Nicole Schaeffer, Senior Vice President- Human Resource and Corporate Services
  • Walter Perkins Ph.D., Chief Technology Officer
  • Eugene Jeffrey Sullivan M.D., Chief Product Strategy Officer and Chief Scientific Officer
  • Mark Quigley, Vice President- Quality Assurance
  • Christine A. Pellizzari, General Counsel, Corporate Secretary
  • Roger Adsett, Chief Commercial Officer
  • Paul Streck, Chief Medical Officer
  • Donald J. Hayden Jr., Non-Executive Chairman of the Board

Who owns Insmed stock?

Insmed's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (14.98%), Palo Alto Investors LLC (9.01%), Vanguard Group Inc. (6.17%), State Street Corp (2.77%), Janus Henderson Group PLC (2.64%) and Emerald Advisers Inc. PA (2.07%). Company insiders that own Insmed stock include Andrew T Drechsler, Christine A Pellizzari, Donald J Hayden Jr, Melvin Md Sharoky, Myrtle S Potter, Orlov S Nicole Schaeffer and William Lewis. View Institutional Ownership Trends for Insmed.

Who sold Insmed stock? Who is selling Insmed stock?

Insmed's stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Goldman Sachs Group Inc., AXA, TD Asset Management Inc., Ameriprise Financial Inc., California State Teachers Retirement System, Cornerstone Capital Management Holdings LLC. and ProShare Advisors LLC. Company insiders that have sold Insmed stock in the last year include Andrew T Drechsler, Donald J Hayden Jr, Melvin Md Sharoky, Myrtle S Potter and Orlov S Nicole Schaeffer. View Insider Buying and Selling for Insmed.

Who bought Insmed stock? Who is buying Insmed stock?

Insmed's stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Emerald Advisers Inc. PA, State Street Corp, Emerald Mutual Fund Advisers Trust, Nexthera Capital LP, Chartwell Investment Partners LLC, Palo Alto Investors LLC and Vanguard Group Inc.. Company insiders that have bought Insmed stock in the last two years include Christine A Pellizzari and William Lewis. View Insider Buying and Selling for Insmed.

How do I buy Insmed stock?

Shares of Insmed can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Insmed's stock price today?

One share of Insmed stock can currently be purchased for approximately $28.42.

MarketBeat Community Rating for Insmed (NASDAQ INSM)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  156 (Vote Outperform)
Underperform Votes:  139 (Vote Underperform)
Total Votes:  295
MarketBeat's community ratings are surveys of what our community members think about Insmed and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Insmed (NASDAQ:INSM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $36.71 (29.18% upside)

Analysts' Ratings History for Insmed (NASDAQ:INSM)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/6/2017Cowen and CompanyReiterated RatingOutperform$54.00HighView Rating Details
9/6/2017Stifel NicolausReiterated RatingBuy$27.00 -> $43.00HighView Rating Details
9/6/2017Robert W. BairdReiterated RatingOutperform -> Positive$23.00 -> $32.00HighView Rating Details
9/6/2017HC WainwrightReiterated RatingBuy$35.00HighView Rating Details
9/5/2017Leerink SwannBoost Price TargetOutperform$27.00 -> $36.00HighView Rating Details
9/5/2017Evercore ISIBoost Price TargetOutperform -> Outperform$28.00 -> $40.00HighView Rating Details
6/11/2017Citigroup Inc.Reiterated RatingNeutral$14.00 -> $17.00HighView Rating Details
8/21/2016Piper Jaffray CompaniesSet Price TargetBuy$24.00N/AView Rating Details
(Data available from 9/25/2015 forward)


Earnings History for Insmed (NASDAQ:INSM)
Earnings by Quarter for Insmed (NASDAQ:INSM)
Earnings History by Quarter for Insmed (NASDAQ INSM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2017Q2 2017($0.63)($0.72)ViewListenView Earnings Details
5/3/2017Q1 2017($0.60)($0.60)$0.30 millionViewListenView Earnings Details
2/23/2017Q316($0.89)($1.10)$0.30 millionViewN/AView Earnings Details
11/3/2016Q216($0.59)($0.61)$0.10 millionViewN/AView Earnings Details
8/4/2016Q2($0.56)($0.59)ViewN/AView Earnings Details
5/5/2016Q1($0.56)($0.54)ViewN/AView Earnings Details
2/25/2016Q415($0.49)($0.51)ViewN/AView Earnings Details
11/6/2015Q315($0.48)($0.50)ViewN/AView Earnings Details
8/6/2015Q2($0.48)($0.47)ViewN/AView Earnings Details
5/7/2015Q115($0.49)($0.55)ViewN/AView Earnings Details
2/27/2015Q414($0.57)($0.36)ViewN/AView Earnings Details
11/6/2014Q314($0.51)($0.54)ViewN/AView Earnings Details
8/6/2014Q214($0.50)($0.59)ViewN/AView Earnings Details
5/8/2014Q114($0.39)($0.36)ViewN/AView Earnings Details
3/6/2014Q413($0.45)($0.41)ViewN/AView Earnings Details
11/5/2013Q313($0.41)($0.46)ViewListenView Earnings Details
8/6/2013Q2 2013($0.32)($0.28)$5.38 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.46)($0.43)ViewListenView Earnings Details
11/7/2012Q312($0.42)($0.38)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Insmed (NASDAQ:INSM)
2017 EPS Consensus Estimate: ($2.40)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.58)($0.58)($0.58)
Q2 20171($0.63)($0.63)($0.63)
Q3 20171($0.59)($0.59)($0.59)
Q4 20171($0.60)($0.60)($0.60)
(Data provided by Zacks Investment Research)


Dividend History for Insmed (NASDAQ:INSM)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Insmed (NASDAQ:INSM)
Insider Ownership Percentage: 5.10%
Institutional Ownership Percentage: 73.08%
Insider Trades by Quarter for Insmed (NASDAQ:INSM)
Institutional Ownership by Quarter for Insmed (NASDAQ:INSM)
Insider Trades by Quarter for Insmed (NASDAQ:INSM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/7/2017Donald J Hayden JrDirectorSell45,000$29.67$1,335,150.00View SEC Filing  
9/6/2017Melvin Md SharokyDirectorSell50,000$27.37$1,368,500.00View SEC Filing  
5/31/2017Christine A PellizzariGeneral CounselBuy10,000$15.14$151,400.00View SEC Filing  
12/15/2016Christine A PellizzariGeneral CounselBuy20,000$12.81$256,200.00View SEC Filing  
12/14/2016Myrtle S PotterDirectorSell6,466$12.79$82,700.14View SEC Filing  
11/14/2016Andrew T DrechslerCFOSell45,000$14.67$660,150.00View SEC Filing  
11/9/2016Orlov S Nicole SchaefferSVPSell68,774$11.95$821,849.30View SEC Filing  
2/1/2016William LewisCEOBuy50,000$13.34$667,000.00View SEC Filing  
9/2/2015Donald J. Hayden, Jr.DirectorSell25,000$24.06$601,500.00View SEC Filing  
5/12/2015Mark QuigleyVPSell18,750$22.07$413,812.50View SEC Filing  
8/13/2014Melvin Md SharokyDirectorBuy88,889$11.25$1,000,001.25View SEC Filing  
11/1/2013William LewisCEOBuy5,233$14.28$74,727.24View SEC Filing  
7/22/2013Fmr LlcInsiderSell158,758$12.02$1,908,271.16View SEC Filing  
7/18/2013Fmr LlcInsiderSell310,227$11.49$3,564,508.23View SEC Filing  
7/15/2013Fmr LlcInsiderSell161,531$10.79$1,742,919.49View SEC Filing  
7/9/2013Fmr LlcInsiderSell146,599$10.01$1,467,455.99View SEC Filing  
7/3/2013Fmr LlcInsiderSell365,779$9.96$3,643,158.84View SEC Filing  
7/1/2013William LewisCEOBuy7,585$9.83$74,560.55View SEC Filing  
6/24/2013Fmr LlcInsiderSell50,000$12.00$600,000.00View SEC Filing  
6/20/2013Fmr LlcInsiderSell143,088$12.24$1,751,397.12View SEC Filing  
6/12/2013Fmr LlcInsiderSell85,758$13.00$1,114,854.00View SEC Filing  
6/6/2013Fmr LlcInsiderSell130,557$12.85$1,677,657.45View SEC Filing  
4/1/2013William LewisCEOBuy9,816$7.58$74,405.28View SEC Filing  
1/9/2013William LewisCEOBuy10,770$6.90$74,313.00View SEC Filing  
12/3/2012William LewisCEOBuy13,568$7.36$99,860.48View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Insmed (NASDAQ:INSM)
Latest Headlines for Insmed (NASDAQ:INSM)
DateHeadline logoCommit To Purchase Insmed At $18, Earn 9.3% Annualized Using Options - September 22 at 1:48 PM logoInsmed Incorporated (INSM) Receives Average Rating of "Buy" from Analysts - September 20 at 2:30 AM logoInsmed to Present at Two September Investor Conferences - GlobeNewswire (press release) - September 19 at 7:58 PM logoInsmed to Present at Two September Investor Conferences - September 19 at 7:58 PM logo Analysts Expect Insmed, Inc. (INSM) Will Announce Earnings of -$0.69 Per Share - September 19 at 10:46 AM logoAs Insmed Reaches New Highs, Is Matinas Following in Its Footsteps? - September 13 at 2:52 AM logoInsmed Announces Closing of Public Offering - September 11 at 8:38 PM logoInsmed Prices Offering At $28.50/Share - September 8 at 11:31 PM logoInsmed prices public offering of common stock - September 7 at 8:10 PM logoInsider Selling: Insmed, Inc. (INSM) Director Sells 45,000 Shares of Stock - September 7 at 7:22 PM logoInsider Selling: Insmed, Inc. (INSM) Director Sells 50,000 Shares of Stock - September 7 at 7:20 PM logoFY2018 EPS Estimates for Insmed, Inc. Cut by Analyst (INSM) - September 7 at 1:36 PM logoInsmed's inhalable amikacin successful in late-stage study - Seeking Alpha - September 7 at 12:54 AM logoBenzinga's Option Alert Recap From September 6 - Benzinga - September 7 at 12:54 AM logoUPDATED: Insmed shares skyrocket 130% on positive late-stage results for rare lung disease therapy - MarketWatch - September 7 at 12:54 AM logoInsmed Announces Pricing of Public Offering of Common Stock - September 7 at 12:54 AM logoInsmed Inc. (INSM) Vaulted To A New High On Phase 3 Study Results - September 6 at 7:54 PM logoInsmed (INSM) Top-line Data Indicates Phase 3 CONVERT Trial Met Primary Endpoint of Culture Conversion - Slideshow - September 6 at 7:53 PM logoToday's Research Reports on Stocks to Watch: Insmed Inc. and XOMA Corporation - September 6 at 7:53 PM logoInsmed Incorporated (INSM) Catches Eye: Stock Soars 119.6% - September 6 at 7:53 PM logoHow Insmed Is Capitalizing on Its Huge Late-Stage Success - September 6 at 7:53 PM logoInsmed's (INSM) Buy Rating Reaffirmed at Stifel Nicolaus - September 6 at 9:33 AM logoInsmed, Inc. (INSM) Given Outperform Rating at Cowen and Company - September 6 at 9:33 AM logoInsmed's (INSM) Positive Rating Reaffirmed at Robert W. Baird - September 6 at 9:17 AM logoInsmed, Inc. (INSM) Rating Reiterated by HC Wainwright - September 6 at 7:40 AM logoInsmed Inc. (INSM) Has Surged To A New High On Phase 3 Study Results - September 6 at 6:25 AM logoInsmed shares skyrocket after lung drug meets key study's main goal - September 6 at 6:24 AM logoUPDATED: Insmed shares skyrocket 130% on positive late-stage results for rare lung disease therapy - September 6 at 6:24 AM logoInsmed More Than Doubles on Late-Stage Trial - September 6 at 6:24 AM logoWhy Did Insmed (INSM) Stock Skyrocket Today? - September 6 at 6:24 AM logoHere's Why Insmed Incorporated Is Skyrocketing - September 6 at 6:24 AM logoInsmed soars on positive lung drug study results - September 6 at 6:24 AM logoInsmed Announces Proposed Public Offering of Common Stock - September 6 at 6:24 AM logoInsmed, Inc. (INSM) Price Target Raised to $36.00 at Leerink Swann - September 5 at 10:28 PM logoInsmed, Inc. (INSM) Price Target Raised to $40.00 - September 5 at 7:48 PM logoHere's Why Insmed Incorporated Is Skyrocketing - September 5 at 2:31 PM logoInsmed Incorporated (INSM) Given Consensus Rating of "Hold" by Brokerages - August 26 at 2:34 AM logoEvercore ISI Initiates Coverage on Insmed, Inc. (INSM) - August 16 at 6:26 PM logoSee what the IHS Markit Score report has to say about Insmed Inc. - August 9 at 8:13 PM logoAre Options Traders Betting on a Big Move in Insmed (INSM) Stock? - August 9 at 8:13 PM logoInsmed, Inc. (NASDAQ:INSM) Downgraded to Sell at BidaskClub - August 5 at 7:26 PM logoForm 8-K INSMED Inc For: Aug 03 - - August 5 at 6:44 PM logoEdited Transcript of INSM earnings conference call or presentation 3-Aug-17 12:30pm GMT - August 4 at 1:03 AM logoBRIEF-Insmed reports Q2 loss per share $0.72 - August 3 at 8:03 PM logoInsmed Reports Second Quarter 2017 Financial Results and Provides Business Update - August 3 at 8:03 PM logoInsmed reports 2Q loss - August 3 at 8:03 PM logoInsmed Incorporated (NASDAQ:INSM) Receives Consensus Recommendation of "Buy" from Brokerages - August 1 at 8:01 AM logoInsmed to Host Second Quarter 2017 Financial Results Conference Call on Thursday, August 3, 2017 - July 27 at 11:00 PM logo-$0.63 EPS Expected for Insmed, Inc. (NASDAQ:INSM) This Quarter - July 26 at 8:22 AM logoImplied Volatility Surging For Insmed, Inc. (INSM) Stock Options - Nasdaq - July 18 at 2:23 AM



Insmed (INSM) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by Staff